The Efficacy of Adipose-Derived Stem Cells (ADSCs) on Chronic Kidney Disease in Dogs

To investigate the therapeutic effect of adipose-derived stem cells (ADSCs) on chronic kidney disease (CKD) in dogs, blood routine examination, urine protein quantitative test, renal function test, urine sediment staining microscopy and B-ultrasonic test of kidney were used to compare the treatment of chronic kidney disease in dogs treated with three different therapies (NT treatment group: traditional supportive therapy group; MT1 treatment group: ADSCs treatment group; MT2 treatment group: NT mixed MT1 treatment group). Results showed that the numbers of red blood cells (RBC), hemoglobin (HGB) and hematocrit (HCT) in MT1 and MT2 treatment groups were higher than those in the NT group, and the urine protein excretion and the levels of serum urea and creatinine in MT1 and MT2 treatment groups were lower than those in the NT treatment group. Besides, there was no further deterioration of kidney morphology in MT1 and MT2 treatment groups. However, a large number of renal tubular epithelial cells and epithelial casts were observed in NT treatment group, while only a small number of renal tubular epithelial cells were observed in MT1 and MT2 treatment groups, indicating the intravenous injection of ADSCs can significantly improve the physical signs and renal function of dogs with CKD, and combined with the traditional therapy, ADSCs has a good prospect for the treatment of CKD in dogs.